What We're Reading: Page 386
Industry reads hand-picked by our editors
Jan 29, 2015
Jan 28, 2015
-
Bloomberg
Expiring patents, surging dollar dog BMS, Pfizer, & Novartis earnings
-
-
UPDATE: Pfizer gives poor nations modest discount after vax price blowback
-
-
-
Rumor mill churns as Duke's Dr. Robert Califf appointed FDA deputy commish
-
-
Average Rx drug prices spiked 10.9% last year
-
Novo deploys 500 rep army to take Saxenda message to MDs
-
Counterfeit Roche cancer drug smuggler gets 30 months in jail
Jan 27, 2015
-
EMA suspending almost 50 drugs over flawed CRO clinical studies
-
Sanofi tops new index that measures pharma's commitment to infectious diseases
-
-
Sanofi/Regeneron off to the races with priority review of cholesterol game-changer
-
Shire pleased as NPS Pharma wins Natpara approval
-
GSK denies reports of imminent job cuts in China
-
-
-
-
-
Jan 26, 2015
-
-
-
UPDATED: Sen. Elizabeth Warren proposes big new pharma fines to fund NIH research
-
Hindsight: Valeant CEO admits mistakes in approach to Allergan bid
-
-
-
-
Regulators get creative on Ebola vaccine testing as infections decline
-
Express Scripts determined to influence prices for cancer drugs
-
Jan 23, 2015
-
-
J&J: Regulatory delays in China are stymying drug approvals
-
-
Out with the old: Merck discontinues US sales of hep C med Victrelis
-
-
Salix Pharma reportedly exploring options, considering sale
-
REPORT: Takeda COO Weber approached for vacant Sanofi CEO post
-
UN Ebola chief requests one last $1 billion in funding to fight outbreak
-
Plaintiffs wanted: Law firms seek shareholders to launch a Sanofi kickback suit
-
Chasing transparency in the pharmaceutical industry: How much is enough?
Jan 22, 2015
-
Obama proposes genetic 'Precision Medicine Initiative' at State of the Union
-
4 key industry trends that will impact biopharma in 2015
-
India issues draft bioequivalence request format for drugs aimed for export
-
UPDATE: Pfizer gives poor nations modest discount after vax price blowback
-
-
J&J's Q4 earnings: A solid 2014
-
-
-
Ambitious RNA biotech Alnylam raising $450M, looking for acquisitions
-
Jan 21, 2015
-
One more push: Senators reintroduce bill to expedite antibiotic approval
-
China FDA to reverse course, allow online Rx drug sales
-
-
Hospira closes North Carolina plant over cost concerns
-
-
AbbVie strikes hep C discount deal with US state-based AIDS programs
-
UPDATED: Yet another major insurance company strikes hep C deal with Gilead
-
-
-
Previous
